Recombinant VWF for Delivery in Women with Von Willebrand Disease
Conclusion:Postpartum blood loss was similar in rVWF and pdVWF treatment groups, whether vaginal or cesarean delivery. Dosing at 80 IU/kg appears safe, but over half developed PPH. Future trials are needed to evaluate blood-volume based VWF dosing to prevent PPH.Table.DisclosuresRagni: Alnylam: Honoraria, Research Funding; Bayer: Consultancy, Provision of Drug for Investigator Initiated Trial; Biomarin: Consultancy, Honoraria, Research Funding; Bioverativ: Consultancy, Research Funding; CSL Behring: Research Funding; MOGAM: Consultancy; NovoNordisk: Research Funding; Opko Biologics: Research Funding; Sangamo: Research Funding; SPARK: Consultancy, Research Funding; Shire: Other: Provision of Drug for Investigator Initiated Trial; Institute for Clinical & Economic Review: Consultancy.
Source: Blood - Category: Hematology Authors: Machin, N., Ragni, M. V. Tags: 322. Disorders of Coagulation or Fibrinolysis: Poster II Source Type: research
More News: Anemia | Bleeding | Cesarean Section | Diabetes | Diabetes Type 1 | Eating Disorders & Weight Management | Endocrinology | Haemophilia | Hemophilia | Hypertension | Insurance | Obesity | Pregnancy | Smokers | Statistics | Students | Study | Universities & Medical Training | von Willebrand Disease | Women